What is Grace Therapeutics, Inc's earnings per share (EPS)?

Grace Therapeutics, Inc (GRCE) reported diluted earnings per share of $-0.47 for fiscal year 2026. This represents a 40.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Grace Therapeutics, Inc Financials

GRCE

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE March

This page shows Grace Therapeutics, Inc (GRCE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GRCE FY2025 2026-06-18

Grace Therapeutics is operating as a cash-funded development business, with equity financing absorbing recurring operating burn while revenue remains absent.

From FY2024 to FY2025, net loss improved from -$12.9M to -$9.6M. But operating cash burn moved the other way, from -$12.3M to -$14.9M, indicating the reported loss looked better even as the core funding need of the business actually increased.

FY2025 ended with $22.1M of cash, about 1.5x that year's operating cash outflow. With total liabilities of just $5.4M and R&D spending of $9.5M, the capital structure looks built to fund development activity, not to support a self-financing operating model.

Shares outstanding climbed from 9.4M in FY2024 to 13.7M in FY2025. Since financing inflow of $14.0M still coincided with cash ending at only $22.1M, the company appears to be using new equity mainly to refill burn rather than to accumulate excess liquidity.

Financial Health Signals

Financial health score pending refresh

We are recalculating Grace Therapeutics, Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Grace Therapeutics, Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.14x

For every $1 of reported earnings, Grace Therapeutics, Inc generates $1.14 in operating cash flow (-$8.9M OCF vs -$7.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$11.1M

YoY+33.6%

Grace Therapeutics, Inc's EBITDA was -$11.1M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 33.6% from the prior year.

Net Income

-$7.8M

YoY+18.6%

Grace Therapeutics, Inc reported -$7.8M in net income in fiscal year 2026. This represents an increase of 18.6% from the prior year.

EPS (Diluted)

$-0.47

YoY+40.5%

Grace Therapeutics, Inc earned $-0.47 per diluted share (EPS) in fiscal year 2026. This represents an increase of 40.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$17.0M

YoY-23.3%

5Y CAGR-19.7%

Grace Therapeutics, Inc held $17.0M in cash against $0 in long-term debt as of fiscal year 2026.

Dividends Per Share

N/A

Shares Outstanding

16M

YoY+18.6%

Grace Therapeutics, Inc had 16M shares outstanding in fiscal year 2026. This represents an increase of 18.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-12.2%

YoY+2.2pp

5Y CAGR+23.1pp

Grace Therapeutics, Inc's ROE was -12.2% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 2.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.4M

YoY-74.7%

5Y CAGR-10.4%

Grace Therapeutics, Inc invested $2.4M in research and development in fiscal year 2026. This represents a decrease of 74.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GRCE Income Statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Revenue	N/A	N/A	N/A	N/A	$100.0M+50920.4%	$196K
Cost of Revenue	N/A	N/A	N/A	N/A	$0-100.0%	$76K
Gross Profit	N/A	N/A	N/A	N/A	$100.0M+83233.3%	$120K
R&D Expenses	$2.4M-74.7%	$9.5M+103.1%	$4.7M-53.0%	$10.0M+79.4%	$5.6M+33.2%	$4.2M
SG&A Expenses	$8.7M+21.0%	$7.2M+7.2%	$6.7M-12.2%	$7.6M-17.8%	$9.3M+67.8%	$5.5M
Operating Income	-$11.1M+33.6%	-$16.7M-29.8%	-$12.9M+75.4%	-$52.2M-234.6%	-$15.6M+5.1%	-$16.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$1.7M+46.9%	-$3.2M-74.6%	-$1.8M+80.8%	-$9.5M-1372.5%	-$648K	$0
Net Income	-$7.8M+18.6%	-$9.6M+25.6%	-$12.9M+69.7%	-$42.4M-332.1%	-$9.8M+50.1%	-$19.7M
EPS (Diluted)	$-0.47+40.5%	$-0.79+41.5%	$-1.35+76.4%	$-5.71	$-0.27	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$462K-18.7%	$568K-40.5%	$955K	N/A	$2.2M-26.3%	$3.0M+9.9%	$2.7M
SG&A Expenses	N/A	$2.0M+1.3%	$2.0M-8.1%	$2.1M	N/A	$1.5M-18.6%	$1.9M-17.7%	$2.3M
Operating Income	N/A	-$2.4M+3.2%	-$2.5M+18.2%	-$3.1M	N/A	-$3.7M+23.3%	-$4.8M+2.7%	-$5.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	N/A	-$605K+29.0%	-$852K-17.7%	-$724K
Net Income	N/A	-$2.3M-146.8%	-$938K+72.1%	-$3.4M	N/A	-$4.2M-21.1%	-$3.4M-31.1%	-$2.6M
EPS (Diluted)	N/A	$-0.14-133.3%	$-0.06+71.4%	$-0.21	N/A	$-0.36-20.0%	$-0.30-25.0%	$-0.24

GRCE Balance Sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Total Assets	$66.7M-7.4%	$72.0M-1.8%	$73.3M-7.4%	$79.1M-38.5%	$128.6M+105.9%	$62.5M
Current Assets	$17.4M-23.5%	$22.7M-5.4%	$24.0M-18.0%	$29.3M-35.3%	$45.3M-27.4%	$62.4M
Cash & Equivalents	$17.0M-23.3%	$22.1M-3.8%	$23.0M-17.5%	$27.9M-8.1%	$30.3M-40.4%	$50.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$722K-10.0%	$802K+46.4%	$548K+3.4%	$530K
Goodwill	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M-37.2%	$13.0M	N/A
Total Liabilities	$2.8M-48.8%	$5.4M-53.4%	$11.6M+3.5%	$11.2M-45.1%	$20.4M+199.4%	$6.8M
Current Liabilities	$2.1M+11.2%	$1.9M+14.6%	$1.7M-50.6%	$3.4M+4.6%	$3.3M+106.5%	$1.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$63.9M-4.1%	$66.6M+7.9%	$61.7M-9.1%	$68.0M-37.2%	$108.3M+94.5%	$55.7M
Retained Earnings	-$228.5M-3.5%	-$220.7M-4.5%	-$211.1M-6.5%	-$198.3M-27.2%	-$155.8M-6.7%	-$146.0M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$66.7M-2.7%	$68.5M+2.9%	$66.6M-4.6%	$69.8M-3.0%	$72.0M+17.6%	$61.2M-6.3%	$65.3M-6.3%	$69.7M
Current Assets	$17.4M-9.5%	$19.2M+11.1%	$17.3M-15.7%	$20.5M-9.6%	$22.7M+90.2%	$11.9M-25.7%	$16.1M-21.4%	$20.4M
Cash & Equivalents	$17.0M-9.1%	$18.7M+10.7%	$16.9M-15.7%	$20.0M-9.6%	$22.1M+100.2%	$11.1M-27.1%	$15.2M-21.9%	$19.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$398K
Goodwill	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M
Total Liabilities	$2.8M-23.3%	$3.6M-4.3%	$3.8M-39.9%	$6.3M+16.2%	$5.4M-40.7%	$9.1M-1.4%	$9.2M-11.0%	$10.4M
Current Liabilities	$2.1M+67.1%	$1.3M+3.1%	$1.2M-46.2%	$2.3M+19.9%	$1.9M-2.1%	$2.0M-26.3%	$2.7M+2.8%	$2.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$63.9M-1.5%	$64.9M+3.3%	$62.8M-1.2%	$63.5M-4.6%	$66.6M+27.8%	$52.1M-7.1%	$56.1M-5.4%	$59.4M
Retained Earnings	-$228.5M-0.5%	-$227.3M-1.0%	-$225.0M-0.4%	-$224.0M-1.5%	-$220.7M+0.3%	-$221.3M-1.9%	-$217.2M-1.6%	-$213.7M

GRCE Cash Flow Statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$8.9M+40.5%	-$14.9M-20.8%	-$12.3M+22.5%	-$15.9M+7.7%	-$17.2M-20.4%	-$14.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0-100.0%	$104K-99.2%	$13.2M+473.5%	-$3.5M+64.3%	-$9.9M
Financing Cash Flow	$3.7M-73.5%	$14.0M+90.7%	$7.4M+2320.7%	$304K	$0-100.0%	$59.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	-$1.7M+24.0%	-$2.2M+29.0%	-$3.1M-74.5%	-$1.8M+39.0%	-$3.0M+28.2%	-$4.1M+2.9%	-$4.2M-17.9%	-$3.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	$0	$0	$0-100.0%	$15K	$0+100.0%	-$15K
Financing Cash Flow	$0-100.0%	$4.0M	$0+100.0%	-$327K-102.3%	$14.0M	$0	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GRCE Financial Ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	N/A	100.0%+38.8pp	61.2%
Operating Margin	N/A	N/A	N/A	N/A	-15.6%+8361.4pp	-8377.0%
Net Margin	N/A	N/A	N/A	N/A	-9.8%+10030.0pp	-10039.8%
Return on Equity	-12.2%+2.2pp	-14.4%+6.5pp	-20.8%+41.6pp	-62.4%-53.4pp	-9.1%+26.3pp	-35.4%
Return on Assets	-11.7%+1.6pp	-13.3%+4.2pp	-17.5%+36.1pp	-53.6%-46.0pp	-7.6%+23.9pp	-31.5%
Current Ratio	8.10-3.7	11.77-2.5	14.26+5.7	8.59-5.3	13.89-25.6	39.50
Debt-to-Equity	0.04-0.0	0.08-0.1	0.19+0.0	0.16-0.0	0.19+0.1	0.12
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-3.6%-2.1pp	-1.5%+3.8pp	-5.3%	N/A	-8.0%-1.9pp	-6.1%-1.7pp	-4.4%
Return on Assets	N/A	-3.4%-2.0pp	-1.4%+3.4pp	-4.8%	N/A	-6.8%-1.5pp	-5.3%-1.5pp	-3.8%
Current Ratio	8.10-6.9	14.96+1.1	13.89+5.0	8.87-2.9	11.77+5.7	6.06+0.1	6.01-1.9	7.86
Debt-to-Equity	0.04-0.0	0.060.0	0.06-0.0	0.10+0.0	0.08-0.1	0.170.0	0.16-0.0	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Plus Therapeutics Inc PSTV

$29.5M

Verrica Pharmaceuticals VRCA

$101.9M

PepGen Inc PEPG

$168.8M

Annovis Bio Inc ANVS

$72.7M

Barinthus Biotherapeutics plc BRNS

$25.0M

Frequently Asked Questions

Is Grace Therapeutics, Inc profitable?

No, Grace Therapeutics, Inc (GRCE) reported a net income of -$7.8M in fiscal year 2026.

What is Grace Therapeutics, Inc's EBITDA?

Grace Therapeutics, Inc (GRCE) had EBITDA of -$11.1M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Grace Therapeutics, Inc's return on equity (ROE)?

Grace Therapeutics, Inc (GRCE) has a return on equity of -12.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Grace Therapeutics, Inc's operating cash flow?

Grace Therapeutics, Inc (GRCE) generated -$8.9M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Grace Therapeutics, Inc's total assets?

Grace Therapeutics, Inc (GRCE) had $66.7M in total assets as of fiscal year 2026, including both current and long-term assets.

How much does Grace Therapeutics, Inc spend on research and development?

Grace Therapeutics, Inc (GRCE) invested $2.4M in research and development during fiscal year 2026.

How many shares does Grace Therapeutics, Inc have outstanding?

Grace Therapeutics, Inc (GRCE) had 16M shares outstanding as of fiscal year 2026.

What is Grace Therapeutics, Inc's current ratio?

Grace Therapeutics, Inc (GRCE) had a current ratio of 8.10 as of fiscal year 2026, which is generally considered healthy.

What is Grace Therapeutics, Inc's debt-to-equity ratio?

Grace Therapeutics, Inc (GRCE) had a debt-to-equity ratio of 0.04 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Grace Therapeutics, Inc's return on assets (ROA)?

Grace Therapeutics, Inc (GRCE) had a return on assets of -11.7% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Grace Therapeutics, Inc's cash runway?

Based on fiscal year 2026 data, Grace Therapeutics, Inc (GRCE) had $17.0M in cash against an annual operating cash burn of $8.9M. This gives an estimated cash runway of approximately 23 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Grace Therapeutics, Inc's Piotroski F-Score?

Grace Therapeutics, Inc (GRCE) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Grace Therapeutics, Inc's earnings high quality?

Grace Therapeutics, Inc (GRCE) has an earnings quality ratio of 1.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.